A new analysis suggests that the doses of rodatristat ethyl — an investigational therapy for pulmonary arterial hypertension (PAH) — now being evaluated in the Phase 2b ELEVATE 2 clinical trial are likely to reduce levels of the hormone serotonin to an extent that has been demonstrated to…
News
Keros Therapeutics’ experimental therapy KER-012 prevented increases in the levels of markers for inflammation, fibrosis (scarring), and heart damage in a rat model of pulmonary arterial hypertension (PAH), a study shows. “We believe that the current study supports that KER-012 has the potential to treat PAH in patients without…
Medical care for patients with pulmonary hypertension (PH) was affected during the first wave of the COVID-19 pandemic, with some patients reporting worsening health and difficulties in accessing expert care, a worldwide survey shows. The results were published in the Orphanet Journal of Rare Diseases, in the…
People with pulmonary hypertension (PH) are invited to apply for $500 micro-grants offered by Team PHenomenal Hope to help cover non-medical needs they are struggling to meet due to the COVID-19 pandemic and how it affected them financially. The grants, offered through nonprofit’s Unmet Needs Patient Impact Fund, can be…
An updated application has been filed with the U.S. Food and Drug Administration (FDA), again asking that LIQ861 be approved as an inhalation treatment of pulmonary arterial hypertension (PAH), its developer Liquidia announced. The company first made this request in an application to the FDA submitted in April 2020. But the…
By screening thousands of potential candidates, researchers have identified a compound, called AG1296, that may be useful for the treatment of pulmonary arterial hypertension (PAH). Their findings were published in the journal Science Translational Medicine, in a study, “iPSC–endothelial cell phenotypic drug screening and in silico…
Altavant Sciences has opened ELEVATE 2, its global Phase 2b clinical trial into the safety and efficacy of rodatristat ethyl, a potential disease-modifying oral therapy for people with pulmonary arterial hypertension (PAH). The…
People with mildly elevated pulmonary arterial pressure (PAP) are at higher risk of progression to pulmonary hypertension (PH) than are those with normal readings, according to a review study. These people should be more closely monitored, and further study is needed to understand how best to treat them to…
Note: This article was updated to include information from a Hopkins study published on May 5, 2021, of responses after a second vaccine dose was given to transplant patients. Long before COVID-19 changed the world, organ transplant recipients were wearing masks to shield themselves from airborne threats. Immunosuppressive medicines, which often…
Activation of a protein called aryl hydrocarbon receptor (AHR) is essential for the development of pulmonary arterial hypertension (PAH), a study found. The findings imply that targeting AHR could be a useful strategy to treat PAH, according to researchers. The results were published in the journal PNAS, in…
On May 5, the Pulmonary Hypertension Association (PHA) will join more than 80 organizations around the world in marking World Pulmonary Hypertension (PH) Day and seeking to raise awareness of the rare disease through webinars and on social media. Part of this year’s focus amid the ongoing…
Iron replacement did not affect disease severity or the ability to function in people with pulmonary arterial hypertension (PAH), an analysis of two clinical studies showed. It also was found to have no impact on quality of life for these patients.
